PepGen Reports Positive Phase 2 DM1 Splicing and Functional Data at 10 mg/kg

What happened

PepGen announced positive results from its Phase 2 FREEDOM2-DM1 trial at the 10 mg/kg dose, reporting the highest splicing correction to date along with improvements across multiple functional measures. This update addresses a key thesis watch item around magnitude of biomarker correction and early functional trends, which were previously unknown. However, the press release omitted any safety data, leaving unresolved the class-wide concerns around peptide-conjugated oligonucleotides, including electrolyte disturbances. The efficacy signal, if confirmed in the full dataset, would support the EDO platform's potential in DM1, but durability and tolerability at higher doses remain critical. Investors should seek the full presentation to assess statistical significance and safety profile before re-rating the stock.

Implication

The reported splicing and functional improvements provide initial clinical validation for PGN-EDODM1 in DM1, potentially supporting a shift from a neutral stance toward a more constructive outlook. However, the lack of safety information in the press release means that class-related tolerability risks, which previously tempered conviction, are not yet alleviated. If the full dataset confirms clean safety and durable efficacy, the stock could see significant re-rating given its micro-cap status and prior skepticism. Conversely, any safety signals or lack of statistical rigor would undermine the positive readthrough. Investors should also monitor competitive developments from Avidity and Dyne, as superior results from rivals could diminish differentiation.

Thesis delta

The prior HOLD/NEUTRAL stance was based on unproven efficacy in DM1 and class-wide safety overhang. Today's reported positive splicing and functional data provide the first clear efficacy signal, shifting the thesis toward cautious optimism. However, the thesis remains gated on safety at higher doses, durability of effect, and confirmation of the full dataset, which prevents a full upgrade to BUY without further evidence.